1. An apparatus for restraining a child with the lap belt and shoulder belt portions of a seat belt of a vehicle, comprising:
a) a safety vest having a front, a rear, first and second sides, and an upper and a lower end for being worn on an upper torso of a child, wherein said safety vest has an inside and outside;
b) closure means being disposed on said front of said safety vest whereby the vest can be placed on the child and then removed from the child; and,
c) first and second spaced and vertically extending slots being disposed on said rear of said safety vest so that the lap belt and shoulder belt portions of the seat belt pass through said first and second slots, said first slot having a separator for separating the lap belt and shoulder belt portions of the seat belt, wherein said first and second slots extend from said outside to said inside of said safety vest so that said first and second slots pass entirely through said safety vest and said seat belt passes between the child and the rear side of said vest and between the first and second slots, wherein said second slot also has a separator whereby said vest is usable for either side of a left or right seated passenger and each separator comprises hook and loop material on each of said first and second slots so that said hook and loop material bridges across opposite sides of said outside portion of each of said first and second slots leaving end portions of said slots open to separate the lap portion from the shoulder portion of the seat belt.
2. The apparatus of claim 1, wherein said safety vest is sleeveless.
3. The apparatus of claim 2, wherein said closure means comprises a zipper being disposed on said front of said safety vest, said zipper extending from said lower end to said upper end of said safety vest.
4. The apparatus of claim 3, wherein said closure means comprises a first hook and loop material flap being disposed on said front of said safety vest, said first hook and loop material flap extending parallel to said zipper from said lower end to said upper end of said safety vest.
5. The apparatus of claim 4, further comprising a single crotch strap having first and second ends, said first end being fixedly connected to said lower end of said rear of said safety vest, said second end being removably connected to said lower end of said front of said safety vest so that said safety vest is secured to the child.
6. The apparatus of claim 5, further comprising a quick release coupling being disposed on said second end of said crotch strap so that said crotch strap can be quickly connected and then disconnected by the child.
7. The apparatus of claim 6, further comprising a second adjustable hook and loop material flap being disposed on each of said first and second sides of said safety vest so that a size of said safety vest can be adjusted to fit the child.
8. The apparatus of claim 7, further comprising a plurality of first snaps for attaching said second adjustable hook and loop material flap to said safety vest.
9. The apparatus of claim 8, further comprising a third adjustable hook and loop material flap being disposed on each shoulder of said safety vest so that the size of said safety vest can be adjusted to fit the child.
10. The apparatus of claim 9, further comprising a plurality of second snaps for attaching said third adjustable hook and loop material flap to said safety rest.
11. The apparatus of claim 1, wherein said safety vest is portable from one vehicle to another vehicle.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for determining a prognosis for mesothelioma in a subject, the method comprising:
(a) providing a biological sample from the subject;
(b) determining the expression level in said sample of a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 1-16, 21-77 and sequences at least about 80% identical thereto; and
(c) comparing said expression level to a threshold expression level, wherein the comparison of the expression level of said nucleic acids to said threshold expression level is indicative of the prognosis of said subject.
2. The method of claim 1, wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NOS: 1-4, 11-12, 21, 22, 27-35, 45-47, 52-59, 70-72 and sequences at least about 80% identical thereto, and wherein an increased expression level of any of said nucleic acid sequence compared to said threshold expression level is indicative of good prognosis of said subject.
3. The method of claim 1, wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NOS: 5-10, 13-16, 23-26, 36-44, 48-51, 60-69, 73-77 and sequences at least about 80% identical thereto and wherein an increased expression level of any of said nucleic acid sequence compared to said threshold expression level is indicative of poor prognosis of said subject.
4. The method of claim 1, wherein the subject is a human.
5. The method of claim 1, wherein said method is used to determine a course of treatment for said subject.
6. The method of claim 1, wherein said biological sample is selected from the group consisting of bodily fluid, a cell line and a tissue sample.
7. The method of claim 6, wherein said bodily fluid is blood.
8. The method of claim 6, wherein said tissue is a fresh, frozen, fixed, wax-embedded or formalin fixed paraffin-embedded (FFPE) tissue.
9. The method of claim 8, wherein said tissue is mesothelium.
10. The method of claim 1, wherein the expression levels are determined by a method selected from the group consisting of nucleic acid hybridization, nucleic acid amplification, and a combination thereof.
11. The method of claim 10, wherein the nucleic acid hybridization is performed using a solid-phase nucleic acid biochip array or in situ hybridization.
12. The method of claim 10, wherein the nucleic acid amplification method is real-time PCR.
13. The method of claim 12, wherein the real-time PCR method comprises forward and reverse primers.
14. The method of claim 13, wherein said forward primer comprises a nucleic acid sequence that is partially complementary to a sequence selected from SEQ ID NO: 116, 21-77 to a fragment thereof or to a sequence at least about 80% identical thereto.
15. The method of claim 13, wherein said forward primer comprises a sequence selected from the group consisting of SEQ ID NOS: 78-100 and sequences at least about 80% identical thereto.
16. The method of claim 13, wherein said reverse primer comprises SEQ ID NO: 124 and sequences at least about 80% identical thereto.
17. The method of claim 13, wherein the real-time PCR method further comprises a probe.
18. The method of claim 17, wherein the probe comprises a sequence complementary to SEQ ID NOS: 1-16, 21-77, to a fragment thereof or to a sequence at least about 80% identical thereto.
19. The method of claim 17, wherein the probe comprises a sequence selected from the group consisting of SEQ ID NOS: 101-123 and sequences at least about 80% identical thereto.
20. A kit for determining a prognosis of a subject with mesothelioma, said kit comprising forward and reverse primers and a probe.
21. The kit of claim 20, wherein said probe comprises a nucleic acid sequence that is complementary to a sequence selected from SEQ ID NO: 1-16, 21-77, to a fragment thereof or to a sequence at least about 80% identical thereto.
22. The kit of claim 20, wherein said probe comprises a sequence selected from the group consisting of SEQ ID NOS: 101-123 and sequences at least about 80% identical thereto.
23. The kit of claim 20, wherein said forward primer is partially complementary to SEQ ID NOS: 1-16, 21-77 to a fragment thereof or to a sequence at least about 80% identical thereto.
24. The kit of claim 20, wherein said forward primer comprises a sequence selected from the group consisting of SEQ ID NOS: 78-100 and sequences at least about 80% identical thereto.
25. The kit of claim 20, wherein said reverse primer comprises a sequence selected from the group consisting of SEQ ID NOS: 124 and sequences at least about 80% identical thereto
26. The kit of claim 17, wherein the kit comprises reagents for performing in situ hybridization analysis.